Copyright 2015 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
In Reply Drs Wagner and Jessen disagree with our conclusion that participants with SCI do not have an increased risk for AD compared with cognitively normal participants. We think that this conclusion is justified because participants with SCI had a similar prevalence of amyloid positivity, the pathological hallmark of AD, as cognitively normal participants.
Wagner and Jessen argue that a meta-analysis1 found that SCI was associated with an increased risk for dementia. However, the outcome measure used in that study was any type of dementia, and therefore it is unclear whether this finding also applies to AD-type dementia.
Jansen WJ, Ossenkoppele R, Visser PJ. Amyloid Pathology, Cognitive Impairment, and Alzheimer Disease Risk—Reply. JAMA. 2015;314(11):1177-1178. doi:10.1001/jama.2015.9719